Suppr超能文献

一项比较普萘洛尔和地尔硫䓬治疗不稳定型心绞痛的随机研究。

A randomized study comparing propranolol and diltiazem in the treatment of unstable angina.

作者信息

Théroux P, Taeymans Y, Morissette D, Bosch X, Pelletier G B, Waters D D

出版信息

J Am Coll Cardiol. 1985 Mar;5(3):717-22. doi: 10.1016/s0735-1097(85)80400-9.

Abstract

One hundred consecutive patients hospitalized in the coronary care unit for unstable angina, excluding patients with Prinzmetal's variant angina, were randomized within 24 hours of admission to treatment with diltiazem (50 patients) or propranolol (50 patients). Also excluded were patients with previous coronary artery bypass surgery and those receiving a beta-receptor blocking agent at the time of hospital admission. Left ventricular function and the extent of coronary artery disease were similar in the two groups. During the hospital stay, the number of chest pain episodes decreased from a mean (+/- SD) of 0.75 +/- 0.1 per patient per day to 0.26 +/- 0.07 (p less than 0.05) with diltiazem and 0.29 +/- 0.1 (p less than 0.05) with propranolol therapy. The circadian distribution of chest pain episodes was affected similarly. After 1 month, 14 of the patients treated with diltiazem were symptom-free compared with 13 treated with propranolol. At a mean follow-up time of 5.1 months (range 1 to 15), death had occurred in two patients in each group and myocardial infarction in five diltiazem- and four propranolol-treated patients (difference not significant). Coronary artery bypass surgery had been performed in 21 diltiazem- and 19 propranolol-treated patients (difference not significant). Only 15 patients were symptom-free, 9 treated with diltiazem and 6 with propranolol. This similar result observed with the two forms of treatment suggests that coronary artery spasm may not be the main factor involved in unstable angina when Prinzmetal's variant angina is excluded. It also suggests that diltiazem can be used as an alternative to the usual treatment with beta-receptor blocking drugs.

摘要

100例因不稳定型心绞痛入住冠心病监护病房的患者(不包括变异型心绞痛患者),在入院24小时内被随机分为两组,分别接受地尔硫䓬治疗(50例)或普萘洛尔治疗(50例)。既往有冠状动脉搭桥手术史的患者以及入院时正在接受β受体阻滞剂治疗的患者也被排除在外。两组患者的左心室功能和冠状动脉疾病程度相似。住院期间,地尔硫䓬治疗组患者胸痛发作次数从平均(±标准差)每天0.75±0.1次降至0.26±0.07次(p<0.05),普萘洛尔治疗组从0.75±0.1次降至0.29±0.1次(p<0.05)。胸痛发作的昼夜分布受到类似影响。1个月后,地尔硫䓬治疗组有14例患者无症状,普萘洛尔治疗组有13例。平均随访时间为5.1个月(范围1至15个月),两组各有2例患者死亡,地尔硫䓬治疗组有5例患者发生心肌梗死,普萘洛尔治疗组有4例(差异无统计学意义)。地尔硫䓬治疗组有21例患者接受了冠状动脉搭桥手术,普萘洛尔治疗组有19例(差异无统计学意义)。只有15例患者无症状,其中9例接受地尔硫䓬治疗,6例接受普萘洛尔治疗。两种治疗方式观察到的相似结果表明,排除变异型心绞痛后,冠状动脉痉挛可能不是不稳定型心绞痛的主要因素。这也表明地尔硫䓬可作为β受体阻滞剂常规治疗的替代药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验